GenePOC obtains CE marked for its GenePOC(TM) Carba test

Québec, Canada (ots) - GenePOC Inc., member of the Debiopharm
Group, announces its third test to be CE marked, the GenePOC Carba
assay, to be used with the revogene(TM) device.

About carbapenem-producing organisms (CPO)

CPO are considered a serious global public health threat and are
associated with significant morbidity, mortality and hospital costs¹.
In 2015, 13 of the 38 countries of the European Union and European
Economic Area (EU-EEA) reported interregional spread or an endemic
situation.² High mortality rates, ranging from 30% to 75%, have been
reported for patients with severe CPO infections.³

About the GenePOC Carba assay

The GenePOC Carba assay is a qualitative, in vitro diagnostic test
designed for the detection and differentiation of the blaKPC, blaNDM,
blaVIM, blaOXA-48-like, and blaIMP gene sequences associated with
carbapenem-non-susceptibility. The assay can provide results from one
up to eight samples in approximately 70 minutes using characterized
carbapenem-non-susceptible isolated colonies of Enterobacteriaceae,
Acinetobacter baumannii, or Pseudomonas aeruginosa.

"The fight against carbapenemase-producing Enterobacteriaceae
(CPE), a rising threat in healthcare facilities, requires rapid and
efficient detection and differentiation" mentioned Professor Thierry
Naas, MD, from the bacteriology services at Hôpital de Bicêtre,
France.

It is important to note that CPO are adapted to spread in
healthcare settings as well as in the community. To prevent
transmission from CPO-positive patients, hospitals should consider
enhanced infection control measures such as contact precautions,
isolation and dedicated nurses for patients who are confirmed
CPO-positive.²

"We are proud to receive the CE marked for our GenePOC Carba
assay" said Patrice Allibert, PhD, CEO of GenePOC. "A test which
offers rapid and accurate results will contribute to the
identification of colonized patients, therefore limit the spread of
these organisms in healthcare settings and save on hospital costs.
Our GenePOC Carba assay also demonstrates the power of our technology
to be compatible with panel detection." concluded Patrice Allibert.

About revogene

The revogene is an automated and stand-alone device, enabling
testing of single-use proprietary microfluidic cartridges with
fluorescence-based real-time polymerase chain reaction technology to
deliver an accurate diagnosis.

About GenePOC

GenePOC, a member of the Debiopharm group, specializes in the
development of diagnostic devices which enable the prevention and
detection of infectious diseases. Further information:
www.genepoc-diagnostics.com

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical group including
five companies active in life sciences. Further information:
www.debiopharm.com.

¹ Borer A et al. Infect Control Hosp Epidemiol. 2009;30(10) :972-6
² http://ots.ch/B2gQp2
³ Tischendorf J. et al. Am J Infect Control. Epub 2016 Feb 15.

Pressekontakt:
Patrice Allibert, CEO
patrice.allibert@genepoc.ca
Tel: +1-418-650-3535

Original-Content von: Debiopharm International SA, übermittelt durch news aktuell